Kodiak Sciences Inc. (KOD) stock
Close on Nov 11, 2026Market cap $6.87BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $6.87B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 546.61
- Dividend yield
- –
- Free cash flow yield
- -2.51%
Fundamentals
- Net income
- -$246.76M
- EPS, diluted
- -$4.08
- Free cash flow
- -$172.81M
- Book value per share
- $0.20
- Diluted shares
- 63M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $108.06
- Open
- $107.90
- Day's range
- $107.25 – $112.31
- Volume
- 689,283
- Average volume (20 days)
- 906,100
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 2.14
- 52-week range
- $18.05 – $112.31
- RSI (14 days)
- 68.4
- Volatility (1 year)
- 205.4%
- Relative volume
- 0.49×
- WACC
- 15.6%
On 1 of our idea list: Insider cluster buys
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | KOD | S&P 500 | Difference | KOD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +9.5% | -2.4% | +11.9 pts | ||
| 3 months | +159.7% | -1.2% | +160.8 pts | ||
| Year to date | +291.1% | +12.3% | +278.8 pts | ||
| 1 year | +457.0% | +12.4% | +444.6 pts | ||
| 3 years | +6257.0% | +78.8% | +6178.2 pts | +299.1% | +21.4% |
| 5 years | -2.5% | +75.2% | −77.6 pts | -0.5% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kodiak Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- News
- Results
About Kodiak Sciences
Biological Products, (No Diagnostic Substances)
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on preventing and treating leading causes of blindness. Utilizing its proprietary Antibody Biopolymer Conjugate platform, the company designs therapeutics for patients with retinal vascular diseases and ocular inflammation. Its pipeline includes tarcocimab tedromer, an investigational anti-VEGF therapy undergoing Phase 3 clinical evaluation for conditions such as diabetic retinopathy and wet age-related macular degeneration. Kodiak is also advancing KSI-501, a bispecific therapy targeting interleukin-6 and VEGF, and KSI-101 for macular edema secondary to inflammation. Additionally, the company develops expanded conjugate technologies and digital health platforms.
Company profile, executives and historyKodiak Sciences stock: common questions
What is Kodiak Sciences's stock price?
KOD closed at $109.34 on Nov 11, 2026, up 1.18% on the day. Over the past 52 weeks it traded between $18.05 and $112.31.
What is Kodiak Sciences's market cap?
Kodiak Sciences was worth $6.87B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is KOD's P/E ratio?
Kodiak Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$4.08), so it has no meaningful P/E ratio.
Does Kodiak Sciences pay a dividend?
No. Kodiak Sciences has not paid a cash dividend over the last twelve months.
When does Kodiak Sciences report earnings next?
Kodiak Sciences is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has KOD stock performed over the past year?
Including dividends, KOD returned +457.0% over the past year, against +12.4% for the S&P 500.
Who are Kodiak Sciences's competitors?
Companies most similar to Kodiak Sciences by business, industry and size include KLRS, OTLK, OCGN, KYMR, ABPO.
See a number that looks wrong?